한올바이오파마

009420KOSPI

55.8 / 100

Reference Date: 2026-09-08

Financial Score14.0 / 40

News Sentiment19.8 / 25

Momentum12.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 2.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hanall BioPharma, established in 1973, focuses on R&D, manufacturing, and sales of synthetic and biopharmaceuticals, with a particular emphasis on developing new drugs for autoimmune diseases, eye conditions, cancer, and neurological disorders. In 2024, the company reported revenue of 138.9 billion KRW, with its subsidiary HPI handling overseas clinical trials and licensing activities.

Number of Employees

315people

Average Salary

82.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

17.93Industry Average 1.200.0Point

14.9x industry avg (risky)

ROE

-3.37Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

11.80Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲7.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼293.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.8% (declining, 3yr)

Detailed News Sentiment

14 totalPositive 12Neutral 2Negative 0Average Sentiment Score 79.3

Positive
자가면역 치료제 '영역 확장' 속도…한올바이오, 하반기 임상 "관심"
한올바이오파마의 FcRn 항체 신약 '아이메로프루바트'가 임상 결과 발표를 앞두고 글로벌 제약업계의 주목을 받고 있어 긍정적인 영향이 예상됩니다.
Neutral
"삼전닉스 '고점 구조대' 온다…실적 믿고 기다려보자"
Positive
대웅제약, '역노화' 핵심기술 美 특허등록 결정…신약 개발 가속
대웅제약의 '역노화' 기술 특허 등록으로 한올바이오파마와 관련된 시장 경쟁 우위 확보 및 신약 개발 가속화 기대.

Detailed Momentum

52-week position6.0Point

52w upper range (62%)

Current 55,500Won52-week high 70,70052-week low 30,700

1-month return4.0Point

1m +2.59% (slight rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14